On 4 February, Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) announced that it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) and the Canadian SEDAR filing system, regarding the Agreement and Plan of Merger and Reorganization (“the Merger Agreement”) with OnCore Biopharma, Inc., a biopharmaceutical company dedicated to discovering, developing and commercializing an all-oral cure for patients suffering from chronic hepatitis B virus (HBV) infection. On Friday shares of Tekmira Pharmaceuticals Corp (NASDAQ:TKMR) closed at $23.09.
Ball Corporation (NYSE:BLL) posted a quarterly profit of $76 million, or $0.54 per share, compared to $124.5 million, or $0.85 per share, in the year-ago period. Excluding non-recurring items, the company earned $0.84 per share. Ball Corporation (NYSE:BLL) in last trading activity fell -1.97% to close at $70.61. Company weekly performance is 11.50% while its quarterly performance stands at 9.69%. Ball Corporation (NYSE:BLL) is -3.93% away from its 52 week high.
Control4 Corporation (NASDAQ:CTRL) reported Q4 EPS of $0.21, $0.02 better than the analyst estimate of $0.19. Revenue for the quarter came in at $41.2 million versus the consensus estimate of $41.93 million. Control4 sees Q1 2015 revenue of $32-35 million, versus the consensus of $38.03 million. On last trading day Control4 Corporation (NASDAQ:CTRL) fell -17.80% to close at $12.98. Its volatility for the week is 4.33% while volatility for the month is 3.74%. CTRL’s sales growth for past 5 years was 17.60% and its EPS growth for past 5 years was 15.00%. Control4 Corporation (NASDAQ:CTRL) monthly performance is -17.95%.
Eagle Bancorp Montana, Inc. (NASDAQ:EBMT) announced its board of directors declared its regular quarterly cash dividend of $0.075 per share. The dividend will be payable March 6, 2015 to shareholders of record February 13, 2015. Eagle Bancorp Montana, Inc. (NASDAQ:EBMT) has 7.70% insider ownership while its institutional ownership stands at 38.00%. In last trading activity company’s stock closed at $11.05.
On 3 February, Bio-Techne Corporation (NASDAQ:TECH), reported a 32.54 percent jump in profit for the quarter ended Dec. 31, 2014. The company has earned $33.21 million, or $0.89 a share in the quarter, compared with $25.06 million, or $0.68 a share for the same period last year. On the other hand, adjusted net income for the quarter stood at $30.34 million, or $0.82 a share compared with $27.59 million or $0.75 a share, a year ago. On last trading day Bio-Techne Corp. (NASDAQ:TECH) decreased -1.33% to close at $90.04. Its volatility for the week is 3.34% while volatility for the month is 2.41%. TECH’s sales growth for past 5 years was 6.30% and its EPS growth for past 5 years was 1.50%. Bio-Techne Corp. (NASDAQ:TECH) monthly performance is -0.79%.